Peter Langmuir, MD
Advertisement
Articles by Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Latest Updated Articles
Dr. Langmuir Discusses Vandetanib Clinical TrialsMarch 15th 2011
Dr. Langmuir Explains the Side Effects of VandetanibApril 7th 2011
Vandetanib Advantages in Medullary Thyroid CancerMarch 15th 2011
Dr. Langmuir on Vandetanib in Medullary Thyroid CancerMarch 15th 2011
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5